In a first-of-its-kind study appearing in Nature Communications, an interdisciplinary team from the university’s Institute for Psychedelics and Neurotherapeutics (IPN) dosed mouse mothers with psilocybin and found that the drug amplified anxiety and depressive-like symptoms associated with perinatal mood disorders — mental health conditions that can arise during or after pregnancy.